Teenager’s Response Supports Pitolisant, Now in Phase 2 Trial, in Easing PWS

Teenager’s Response Supports Pitolisant, Now in Phase 2 Trial, in Easing PWS

303163

Teenager’s Response Supports Pitolisant, Now in Phase 2 Trial, in Easing PWS

Pitolisant, a treatment for narcolepsy, should be considered for people with Prader-Willi syndrome (PWS) whose response to psychotropic medications is less than optimal, a case report of a 15-year-old patient suggests. “Pitolisant has the potential to improve many symptoms in patients with Prader-Willi syndrome and it appears to be well tolerated with minimal side effects observe,” its scientists wrote. The report, “Pitolisant in an Adolescent with Prader-Willi Syndrome,” was published in The Journal of Pediatric Pharmacology…

You must be logged in to read/download the full post.